Downregulation of urinary cell‐free microRNA‐214 as a diagnostic and prognostic biomarker in bladder cancer

Wang, Jinfeng; Zhang, Xin; Wang, Lili; Dong, Zhaogang; Li, Du; Yang, Yongmei; Guo, Yuan; Wang, Chuanxin

doi:10.1002/jso.23937

Cited by 57 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Wang et al . 18 also found that a shorter OS in BC patients with an decreased level of miR-214 (HR, 0.28; 95% CI: 0.16–0.50; p < 0.001) (Fig. 3E).…”

Section: Resultsmentioning

confidence: 52%

“…Six prognostic miRs (miR-21, miR-143, miR-155, miR-200, miR-214, and miR-222) in BC repeatedly appeared in the included studies and triggered a meta-analysis. Only 12 articles evaluating the relationship between six specific miRs and BC prognosis satisfied the criteria for meta-analysis 14, 16, 18–27 . Figure 1 shows a flowchart of the study selection process.…”

Section: Resultsmentioning

confidence: 99%

“…Two studies addressed the relationship between miR-214 expression and survival outcomes in BC, of which two contained RFS 18, 24 data, and one contained OS 18 data. A meta-analysis was conducted on the miR-214 expression and RFS relationship.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis

Xie

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to systematically review articles that investigated the prognostic significance of different microRNAs in bladder cancer (BC). We systematically searched PubMed, Web of Science, and Embase to identify relevant studies until March 2016. After screening, 26 studies that involved 2753 patients were included. Results suggested that many miRs expression aberration may predict prognosis in patients with BC. There are six miRs (miR-21, miR-143, miR-155, miR-200, miR-214, and miR-222) were reported by at least two studies, and we performed meta-analysis in the corresponding studies. Accordingly, we found that high miR-21 expression was associated with poor overall survival [OS; hazard ratio (HR) = 3.94, 95% CI 2.08–7.44]. High miR-143 expression was associated with poor progression-free survival (PFS; HR = 3.78, 95% CI 1.61–8.89). High miR-155 expression was associated with poor PFS (HR = 8.10, 95% CI 2.92–22.48). High miR-222 expression was associated with poor OS (HR = 3.39, 95% CI 1.10–10.41). Meanwhile, low miR-214 expression was correlated with poor RFS(HR = 0.34, 95% CI 0.22–0.53). Our comprehensive systematic review concluded that microRNAs, particularly miR-21, miR-143, miR-155, miR-214, and miR-222, could serve as meticulous follow-up markers for early detection of progression or recurrence and even useful therapeutic targets for the treatment in patients with BC.

show abstract

“…In addition, Wang et al . 18 also found that a shorter OS in BC patients with an decreased level of miR-214 (HR, 0.28; 95% CI: 0.16–0.50; p < 0.001) (Fig. 3E).…”

Section: Resultsmentioning

confidence: 52%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis

Xie

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Bladder cancer (BC), characterized by frequent recurrence and high mortality, is one of the most common urologic malignancy over the world, with 79030 newly estimated cases and 16870 newly estimated deaths in U.S.A. in 2017 [1,2]. Although the majority of BCs are non-invasive (70–75%), they will metastasize over time and eventually progress to muscle-invasive disease (25–30%) [3].…”

Section: Introductionmentioning

confidence: 99%

High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer

et al. 2018

View full text Add to dashboard Cite

The advent of high-throughput sequencing methods has facilitated identification of novel long non-coding RNAs (lncRNAs), which have been demonstrated to play an important role in multiple tumors. Moreover, with the assistance of bioinformatics analysis, LINC01605 has been found to be up-regulated in bladder cancer (BC) tissues compared with normal tissues. Hence, the present study was to explore its specific biological role and related mechanism in BC. The relative expression level of LINC01605 was measured in a cohort of BC tissues with matched normal tissues as well as human BC cell lines by quantitative real-time PCR (qRT-PCR). Survival analysis was performed to explore the relationship between LINC01605 expression and the prognosis of BC patients. The biological function of LINC01605 was studied in vitroand in vivo, by means of CCK-8 assay, colony formation assay, transwell assay, and tumor xenografts mice model. LINC01605 was found to be frequently highly expressed in both human BC cells and tissues. Survival analysis indicated that high LINC01605 expression was associated with higher histological grade and clinical stages. In addition, down-regulated LINC01605 in BC cells could significantly inhibit the abilities of proliferation, migration, and invasion in vitro and knockdown of LINC01605 in subcutaneous xenograft tumor model could impede tumorigenesis in vivo. Mechanistically, LINC01605 could activate epithelial–mesenchymal transition (EMT) signaling pathway and promote the expression of matrix metallopeptidase (MMP) 9 (MMP9). In summary, our results shed light on that LINC01605, as a new prognostic biomarker, could promote the proliferation, migration, and invasion of BC cells via activating EMT signaling pathway and up-regulating MMP9 expression.

show abstract

“…Although urinary miRNAs have been investigated as promising diagnostic and prognostic indicators of malignancy, the technology requires improvement before its clinical application . Because no consensus housekeeping miRNAs have been identified to date, alternative markers such as U6 miRNA are used as internal controls . However, test results vary according to the used internal control.…”

Section: Introductionmentioning

confidence: 99%

Urinary cell‐free microRNA biomarker could discriminate bladder cancer from benign hematuria

Piao

Jeong

Kim

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under nonmalignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria. A multicenter study was performed using 543 urine samples obtained from the National Biobank of Korea, including 326 BC, 174 hematuria and 43 pyuria without cancer. The urinary miR-6124 to miR-4511 ratio was considerably higher in BC than in hematuria or pyuria, and enabled the discrimination of BC from patients with hematuria at a sensitivity of >90% (p < 0.001). Conclusively, the proposed noninvasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer.

show abstract

Downregulation of urinary cell‐free microRNA‐214 as a diagnostic and prognostic biomarker in bladder cancer

Abstract: Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer.

Cited by 57 publications

References 28 publications

MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis

MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis

High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer

Urinary cell‐free microRNA biomarker could discriminate bladder cancer from benign hematuria

Contact Info

Product

Resources

About